SCHEMBL7920951

SCHEMBL7920951

COCC(C)(C)NCc1ccc(F)cc1F

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.41
AGXT P21549 2/20 0.41
KDM4E B2RXH2 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RIPK1 Q13546 2/20 0.37
GAA P10253 1/20 0.36
MAOB P27338 1/20 0.35
P2RX7 Q99572 2/20 0.34
PDE10A Q9Y233 1/20 0.34
ALDH1A1 P00352 2/20 0.34
ACHE P22303 2/20 0.33
KCNK3 O14649 1/20 0.33
KCNK5 O95279 1/20 0.33
KCNA5 P22460 1/20 0.33
KCNK17 Q96T54 1/20 0.33
KCNK9 Q9NPC2 1/20 0.33
BCHE P06276 1/20 0.33
BACE1 P56817 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7920998 0.81 IDO1 (0.40) IDO1AGXTKDM4ESMN1; SMN2RIPK1
SCHEMBL7922884 0.80 IDO1 (0.48) IDO1AGXTKDM4ESMN1; SMN2RIPK1
SCHEMBL26530446 0.73 IDO1 (0.46) IDO1AGXTKDM4ESMN1; SMN2GAA
SCHEMBL6077476 0.73 IDO1 (0.48) IDO1AGXTKDM4ESMN1; SMN2GAA
SCHEMBL9074382 0.72 RIPK1 (0.43) IDO1AGXTKDM4ESMN1; SMN2RIPK1
SCHEMBL7922784 0.72 IDO1 (0.41) IDO1AGXTKDM4ESMN1; SMN2RIPK1
SCHEMBL2095744 0.70 SLC6A4 (0.49) IDO1AGXTKDM4ESMN1; SMN2GAA
SCHEMBL706473 0.70 IDO1 (0.64) IDO1AGXTKDM4ESMN1; SMN2RIPK1
SCHEMBL19121691 0.69 RIPK1 (0.47) KDM4ESMN1; SMN2RIPK1
SCHEMBL6415999 0.69 CES2 (0.45) SMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6194461-B1 USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-02-27 US disclosed
EP-0945426-A1 NITRONE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1999-09-29 EP disclosed